Physician profile
Michael B Hemphill
NPI 1902812571
$90,432.91
in general payments reported to CMS, 2019-2025
81 companies · $3,834 in 2025
The $3,834 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,922 · 2021: $18K · 2022: $29K · 2023: $18K · 2024: $6,731 · 2025: $3,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $9,818 · Honoraria: $788 · Travel and Lodging: $620 · Education: $77.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,564.00 |
| Food and Beverage | $9,818.17 |
| Honoraria | $788.00 |
| Travel and Lodging | $620.13 |
| Education | $77.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44,839.78 | 2019-2025 | Vyloy, Padcev, Veozah |
| Astellas Pharma Global Development | $13,720.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $7,923.77 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Karyopharm Therapeutics INC. | $1,976.04 | 2020-2025 | Xpovio |
| Catalyst Pharmaceuticals, INC. | $1,500.00 | 2021 | |
| Seagen INC. | $1,477.31 | 2019-2023 | Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $1,277.89 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $1,248.09 | 2022-2024 | Fotivda |
| Taiho Oncology, INC. | $1,211.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,116.56 | 2019-2025 | Gilotrif |
| Puma Biotechnology, INC. | $1,092.29 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $917.01 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $903.11 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $898.22 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Blueprint Medicines Corporation | $831.88 | 2023-2024 | Ayvakit |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $780.10 | 2019-2025 | |
| Amgen INC. | $519.22 | 2019-2025 | Uplizna, Vectibix, Xgeva |
| Celgene Corporation | $514.99 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $463.07 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Beigene, LTD. | $450.00 | 2020 | |
| Eisai INC. | $442.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $434.37 | 2019-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $429.20 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Pfizer INC. | $367.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $332.54 | 2019-2025 | |
| Biogen, INC. | $313.04 | 2019-2020 | |
| Gilead Sciences, INC. | $269.69 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $239.85 | 2019-2025 | Venclexta, Itovebi, Tecentriq |
| Emd Serono, INC. | $228.50 | 2019-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $219.86 | 2019-2025 | Ultomiris |
| Tersera Therapeutics LLC | $202.34 | 2022-2025 | Xermelo, Zoladex |
| Abbvie INC. | $181.61 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.31 | 2019-2025 | Ninlaro |
| Sanofi-Aventis U.S. LLC | $169.50 | 2019 | |
| Exelixis INC. | $155.05 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $153.65 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genmab U.S., INC. | $141.79 | 2024-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $139.90 | 2019-2025 | Onivyde |
| Mirati Therapeutics, INC. | $139.26 | 2023-2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $119.82 | 2024-2025 | Provenge |
| Pharmaessentia USA Corporation | $110.71 | 2024-2025 | Besremi |
| Lexicon Pharmaceuticals, INC. | $108.98 | 2019-2020 | |
| Sobi, INC | $98.16 | 2025 | |
| Array Biopharma INC | $94.80 | 2019-2025 | Braftovi, Mektovi, Xalkori |
| Adc Therapeutics America, INC. | $88.86 | 2024-2025 | |
| Shield Therapeutics INC | $77.74 | 2024 | |
| Jazz Pharmaceuticals INC. | $74.99 | 2024-2025 | |
| Morphosys, US INC. | $70.58 | 2022-2023 | Monjuvi |
| Beigene USA, INC. | $70.34 | 2023-2024 | Brukinsa |
| Agios Pharmaceuticals, INC. | $67.72 | 2019-2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $63.59 | 2019-2024 | Rezlidhia, Tavalisse |
| Teva Pharmaceuticals USA, INC. | $62.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $59.57 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Legend Biotech USA INC. | $57.57 | 2025 | Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $51.47 | 2019-2023 | Imbruvica |
| Verastem, INC. | $50.35 | 2019 | |
| Aurobindo Pharma USA, INC. | $48.08 | 2019 | |
| Dova Pharmaceuticals | $44.36 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $44.24 | 2024-2025 | Monoferric, Cosela |
| Beone Medicines USA, INC. | $43.86 | 2025 | Tevimbra |
| Janssen Pharmaceuticals, INC | $43.45 | 2024 | Xarelto |
| Deciphera Pharmaceuticals INC. | $43.16 | 2024-2025 | Qinlock, Romvimza |
| Caris Mpi, INC. | $41.78 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $35.90 | 2023 | Vonjo |
| Kite Pharma, INC. | $31.51 | 2020-2023 | Yescarta |
| Kyowa Kirin, INC. | $29.65 | 2024 | Poteligeo |
| Stemline Therapeutics INC. | $28.47 | 2023 | Orserdu |
| Sandoz INC. | $27.69 | 2024 | |
| Genentech, INC. | $26.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.99 | 2024 | Givlaari |
| Geron Corporation | $23.55 | 2025 | Rytelo |
| Organon LLC | $23.19 | 2023 | Ontruzant |
| Sumitomo Pharma America, INC. | $21.96 | 2024 | Orgovyx |
| Cycle Pharmaceuticals INC | $20.55 | 2025 | Phyrago |
| Syndax Pharmaceuticals, INC. | $20.01 | 2025 | |
| Clovis Oncology, INC. | $19.66 | 2019 | |
| Biocompatibles, INC. | $19.57 | 2019 | |
| Fennec Pharmaceuticals, INC. | $15.43 | 2025 | Fyarro |
| Tolmar Pharmaceuticals, INC. | $14.24 | 2019 | |
| Fortovia Therapeutics, INC. | $13.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hemphill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.